首頁 > 市場調查報告書 > 製藥

製藥企業製藥企業資料製藥企業策略

市場調查報告書

商品編碼

1708060

腫瘤學領域的共同研究及授權契約:2020年～2025年

Oncology Collaboration and Licensing Deals 2020-2025

出版日期: 2025年04月01日 | 出版商:

Current Partnering | 英文 1500+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

《腫瘤學合作與許可交易》提供了前所未有的途徑，可以全面了解全球領先的生物製藥公司正在進行的腫瘤學交易。

本報告提供了 2020 年至 2025 年 3,350 筆腫瘤學交易的詳細資訊。

此報告提供雙方宣布的交易的付款條款。這些數據為付款條款和其他貿易條款提供了有用的見解。

了解潛在合作夥伴談判的交易條款的靈活性，可以為談判過程提供重要的見解，讓您了解在談判條款時可以期望實現的目標。許多小型企業可能會想要詳細的付款條款，但當涉及到如何產生付款以及如何轉移權利時，細節決定成敗。

本報告提供了當前協議交易和合作資料庫中記錄的自 2020 年以來宣布的合作和許可協議的綜合清單。

報告的第一章介紹了腫瘤學領域的交易和商業活動。第 1 章對報告進行了介紹，第 2 章分析了腫瘤學領域的交易趨勢。

第 3 章介紹了腫瘤學領域已達成交易的財務條款和發展階段。交易按標題價值、預付款、里程碑和特許權使用費列出並分為幾個部分。

第 4 章回顧了在腫瘤學交易中最活躍的 25 家生物製藥公司。對於與美國證券交易委員會 (SEC) 公開宣布的協議交易，可以透過目前協議交易和聯盟資料庫中的連結在線存取這些協議。

第 5 章全面深入地回顧了 2020 年以來簽署和宣布的腫瘤學交易，並提供合約文件。每個交易標題都透過網路連結連結到實際合約文件的線上版本，從而可以輕鬆根據需要存取每個合約文件。

第 6 章提供了按目標分類的腫瘤學病例綜合目錄。

該報告還包括大量圖表和圖形，重點介紹了 2020 年及以後的腫瘤學承包趨勢和活動。

此外，我們的綜合貿易目錄按公司 A-Z 和技術類型進行組織。每個交易標題都包含一個指向在線交易記錄的網絡鏈接，以及（如果有）合同文件的網絡鏈接，以便根據需要輕鬆訪問每個文件。

主要優點

腫瘤學研究合作和授權協議為讀者提供了以下主要好處：

了解 2020 年及以後的合約趨勢
瀏覽腫瘤學合作與許可機會
基準分析 - 確定交易的市場價值
財務條款 – 預付款、里程碑付款、特許權使用費
依公司 A-Z、治療目標、技術類型劃分的交易目錄
大額交易金額
最活躍的交易者
確定每筆交易的資產和條款
查閱合約文件－洞察交易結構
盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性。
節省數百小時的研究時間

研究範圍

腫瘤學研究合作與許可協議旨在從全球領先的生物製藥公司更深入地了解腫瘤學趨勢和交易結構。

回報內容

生物製藥產業腫瘤學領域的交易趨勢
合作與授權交易結構概述
涵蓋製藥和生物技術的腫瘤學交易記錄目錄
主要腫瘤學交易（各價值）
最活躍的腫瘤學許可交易促成者

簡介
按腫瘤治療標的交易
交易名錄
交易目錄 - 2020 年至 2025 年腫瘤學交易（依公司劃分）
交易目錄 - 按技術類型劃分的腫瘤學交易（2020-2025 年）
定義交易類型
關於 Biopharma Research Ltd
當前合作夥伴關係
當前合約
Current Partnering 的最新報告標題

簡介目錄

Product Code: CP2201

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 3,350 oncology deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2020
Browse oncology collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

Trends in oncology dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of oncology deal records covering pharmaceutical and biotechnology
The leading oncology deals by value
Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?